Radiopharm Theranostics Limited (RADX)
Radiopharm Theranostics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Carlton, VIC, AU. The stock last traded at $2.81, down 1.57% on the session, giving a market capitalisation of $3.6M. On trailing twelve-month figures it carries a trailing P/E of -0.78, a net margin of -364.0%. Its beta of 0.80 implies it has historically moved less than the broad market.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Radiopharm Theranostics Limited is most often compared with the following Healthcare names: